Vaccine Candidates against Arenavirus Infections

Takeshi Saito, Rachel A. Reyna, Satoshi Taniguchi, Kirsten Littlefield, Slobodan Paessler, Junki Maruyama

Research output: Contribution to journalReview articlepeer-review


The viral family Arenaviridae contains several members that cause severe, and often lethal, diseases in humans. Several highly pathogenic arenaviruses are classified as Risk Group 4 agents and must be handled in the highest biological containment facility, biosafety level-4 (BSL-4). Vaccines and treatments are very limited for these pathogens. The development of vaccines is crucial for the establishment of countermeasures against highly pathogenic arenavirus infections. While several vaccine candidates have been investigated, there are currently no approved vaccines for arenavirus infection except for Candid#1, a live-attenuated Junin virus vaccine only licensed in Argentina. Current platforms under investigation for use include live-attenuated vaccines, recombinant virus-based vaccines, and recombinant proteins. We summarize here the recent updates of vaccine candidates against arenavirus infections.

Original languageEnglish (US)
Article number635
Issue number3
StatePublished - Mar 2023


  • Junin virus
  • Lassa virus
  • arenavirus
  • vaccine
  • virus attenuation

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Drug Discovery
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'Vaccine Candidates against Arenavirus Infections'. Together they form a unique fingerprint.

Cite this